menu
    • menu
    [{"orgOrder":0,"company":"Primo Biotechnology","sponsor":"Kaohsiung Chang Gung Memorial Hospital,Taiwan","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"18-F PSMA","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Primo Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Primo Biotechnology \/ Kaohsiung Chang Gung Memorial Hospital,Taiwan","highestDevelopmentStatusID":"6","companyTruncated":"Primo Biotechnology \/ Kaohsiung Chang Gung Memorial Hospital,Taiwan"},{"orgOrder":0,"company":"Primo Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Radiolabeled Compound","year":"2025","type":"Series A Financing","leadProduct":"PB011","moa":"PSMA","graph1":"Oncology","graph2":"Phase II","graph3":"Primo Biotechnology","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Primo Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Primo Biotechnology \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Primo Biotechnology

    Menu

    Primo Biotechnology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Primo Biotechnology

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Primo Biotechnology

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PB011

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $17.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Primo Biotechnology Secures A Funding to Strengthen Global Radiopharmaceutical Strategy

                            Details : Primo will be advancing clinical trial plans for pipeline candidates PB011 and PB012 to expand into other cancer indications.

                            Product Name : PB011

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            July 02, 2025

                            Lead Product(s) : PB011

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $17.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Primo Biotechnology

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Primo Biotechnology

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F PSMA

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Kaohsiung Chang Gung Memorial Hospital,Taiwan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Detecting Colorectal Cancer With Liver Metastatic Lesions Using Novel Precise Imaging Tools

                            Details : 18-F PSMA is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colonic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            April 20, 2025

                            Lead Product(s) : 18-F PSMA

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Kaohsiung Chang Gung Memorial Hospital,Taiwan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth